# L. Puig

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/l-puig/

## Facts

| Field | Value |
| --- | --- |
| Citations | 29,812 |
| Field | Psoriasis: Treatment and Pathogenesis |
| h-index | 76 |
| i10-index | 450 |
| Last Known Institution | Universitat Autònoma de Barcelona |
| OpenAlex ID | https://openalex.org/A5033015474 |
| ORCID iD | https://orcid.org/0000-0001-6083-0952 |
| Works | 990 |

## Researcher papers

- [Epidemiology of atopic dermatitis in adults: Results from an international survey](https://scholariq.org/papers/epidemiology-of-atopic-dermatitis-in-adults-results-from-an-international-survey/)
- [Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis](https://scholariq.org/papers/phase-3-studies-comparing-brodalumab-with-ustekinumab-in-psoriasis/)
- [Psoriasis and Systemic Inflammatory Diseases: Potential Mechanistic Links between Skin Disease and Co-Morbid Conditions](https://scholariq.org/papers/psoriasis-and-systemic-inflammatory-diseases-potential-mechanistic-links-between/)
- [Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials](https://scholariq.org/papers/efficacy-and-safety-of-risankizumab-in-moderate-to-severe-plaque-psoriasis/)
- [Patient perspectives in the management of psoriasis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey](https://scholariq.org/papers/patient-perspectives-in-the-management-of-psoriasis-results-from-the-population/)
- [Development and validation of the International Hidradenitis Suppurativa Severity Score System ( <scp>IHS</scp> 4), a novel dynamic scoring system to assess <scp>HS</scp> severity](https://scholariq.org/papers/development-and-validation-of-the-international-hidradenitis-suppurativa/)
- [Comparison of Biologics and Oral Treatments for Plaque Psoriasis](https://scholariq.org/papers/comparison-of-biologics-and-oral-treatments-for-plaque-psoriasis/)
- [Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council](https://scholariq.org/papers/recategorization-of-psoriasis-severity-delphi-consensus-from-the-international/)
- [Prevalence of most common skin diseases in Europe: a population‐based study](https://scholariq.org/papers/prevalence-of-most-common-skin-diseases-in-europe-a-population-based-study/)
- [Factors associated with adverse COVID-19 outcomes in patients with psoriasis—insights from a global registry–based study](https://scholariq.org/papers/factors-associated-with-adverse-covid-19-outcomes-in-patients-with-psoriasis/)

## Researcher topics

- [Psoriasis: Treatment and Pathogenesis](https://scholariq.org/topics/psoriasis-treatment-and-pathogenesis/)
- [Dermatology and Skin Diseases](https://scholariq.org/topics/dermatology-and-skin-diseases/)
- [Spondyloarthritis Studies and Treatments](https://scholariq.org/topics/spondyloarthritis-studies-and-treatments/)
- [Health Systems, Economic Evaluations, Quality of Life](https://scholariq.org/topics/health-systems-economic-evaluations-quality-of-life/)
- [Autoimmune Bullous Skin Diseases](https://scholariq.org/topics/autoimmune-bullous-skin-diseases/)

## Researcher university

- [Universitat Autònoma de Barcelona](https://scholariq.org/institutions/universitat-autonoma-de-barcelona/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.